Medicenna Therapeutics Corp. MDNAF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -7.41% | 0.81% | 1.39% | -25.06% | 2.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.09% | 6.50% | 10.14% | -1.99% | 34.86% |
| Operating Income | 1.09% | -6.50% | -10.14% | 1.99% | -34.86% |
| Income Before Tax | -3.08% | -473.17% | 15.59% | -16.13% | -34.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.08% | -473.17% | 15.59% | -16.13% | -34.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.08% | -473.17% | 15.59% | -16.13% | -34.01% |
| EBIT | 1.09% | -6.50% | -10.14% | 1.99% | -34.86% |
| EBITDA | 0.82% | -6.60% | -10.49% | 1.94% | -34.56% |
| EPS Basic | 1.85% | -449.06% | 21.05% | -7.05% | -19.67% |
| Normalized Basic EPS | 1.85% | -450.00% | 20.88% | -7.26% | -19.47% |
| EPS Diluted | 1.85% | -449.06% | 21.05% | -7.05% | -19.67% |
| Normalized Diluted EPS | 1.85% | -450.00% | 20.88% | -7.26% | -19.47% |
| Average Basic Shares Outstanding | 4.99% | 6.69% | 6.93% | 8.55% | 12.09% |
| Average Diluted Shares Outstanding | 4.99% | 6.69% | 6.93% | 8.55% | 12.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |